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ABSTRACT
Desmoid tumors develop from connective tissue, fasciae, and aponeuroses, and may occur in the context of familial 
adenomatous polyposis or may arise sporadically; also, they may be extra-abdominal, intra-abdominal, or located in 
the abdominal wall. These benign tumors have a great aggressiveness with a high rate of local recurrence. Familial 
adenomatous polyposis is an inherited condition with autosomal dominant transmission, and is characterized by the 
development of multiple colonic and rectal adenomatous polyps, as well as desmoid tumors. We present the case of a 
54-year-old woman with germline APC gene mutation, who underwent a total colectomy, subsequently developing two 
large infiltrative solid intra-abdominal lesions consistent with desmoid tumors. Medical treatment with Cox-2 inhibitors 
was initiated without result. She was submitted to resection for intestinal obstruction, but developed local recurrence. 
The lesions were also unresponsive to tamoxifen, and chemotherapy was initiated with dacarbazine plus doxorubicin, 
switching to vinorelbine plus methotrexate, achieving a good response in all lesions after 12 months. The approach to these 
intra-abdominal lesions should be progressive, beginning with observation, then a medical approach with non-steroidal 
anti-inflammatory drugs or with an anti-hormonal agent. Afterwards, if progression is still evident, chemotherapy should 
be started. Surgery should be reserved for resistance to medical treatment, in palliative situations, or for extra-abdominal 
or abdominal wall desmoids tumors. 
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INTRODUCTION
Desmoid tumors (DT) develop from connective 
tissue, fasciae, and aponeuroses,1,2 corresponding 
to a monoclonal proliferation of well-differentiated 
fibroblasts.3-5 This can occur in the context of familial 
adenomatous polyposis (FAP), or may arise sporadically; 
also they may be extra-abdominal, intra-abdominal, or 
located in the abdominal wall.5 DT is considered a 
benign neoplasm due to the absence of metastasis, but 
has a great local aggressiveness, given the infiltrative 
growth and the invasion of adjacent structures,6 with 
a high local recurrence rate, ranging from 25% to 
85%.2,7
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The familial form of this neoplasm may occur 
between 10% and 25% of FAP patients and is 
attributed to a germline mutation in the adenomatous 
polyposis coli (APC) gene.8,9 The carriers of these 
mutations have “850 times greater risk than the 
general population.”2,10 The sporadic forms of 
DT result from somatic mutations in the APC or the 
beta-catenin genes5,11 and are relatively rare, affecting 
approximately two to five individuals per million per 
year in the general population.12,13
FAP is an inherited condition “that results from 
the autosomal dominant transmission of a germline 
mutation in the APC tumor suppressor gene,” which 
is located on the long arm of chromosome 5.10 
This pathology is characterized by the development 
of several (hundreds to thousands) of adenomatous 
polyps in the colon and rectum, with a subsequent risk 
of developing colorectal carcinoma.14 These patients 
have the risk of extra-colic manifestations like DT, 
upper gastrointestinal tract adenomas, osteomas, 
epidermoid cysts, as well as thyroid, adrenal gland, and 
central nervous system neoplasms.7 Of these, DT are 
the most frequent cause of death (after colorectal 
carcinoma) in patients with FAP, with mortality 
ranging from 18% to 31% (more than periampullary 
carcinomas at about 22%).15
CASE REPORT
We present the case of a 54-year-old woman 
with FAP in the context of germline APC mutation. 
She had undergone an open total colectomy 8 years 
before, after more than 10 years of endoscopic 
surveillance. Pathology revealed one site with an in 
situ adenocarcinoma (without positive nodes on the 
68 isolated) and more than 100 adenomatous polyps 
with dysplasia. The patient preferred to preserve the 
rectum and maintain endoscopic surveillance.
Du r ing  fo l l ow-up ,  an  i n f i l t r a t i v e  so l i d 
intra-abdominal lesion in the root of the mesentery 
was identified in computed tomography and confirmed 
by magnetic resonance imaging. The hypothesis of 
peritoneal carcinomatosis was raised. A surgical biopsy 
was performed, revealing a fusiform cell tumor, which 
was consistent with reactive fibrosis.
At a multidisciplinary meeting, since the lesion 
was large, it was decided to initiate medical treatment 
with Cox-2 inhibitors, but no therapeutic response 
was observed. The disease progressed, and an 
intestinal obstruction developed due to a new 
lesion in the root of the mesentery, which measured 
157 × 140 × 95 mm. Therefore, the patient underwent 
an en-bloc segmental enterectomy and R2 resection 
of the retroperitoneal tumor, with histological 
confirmation of a DT (Figure 1A-D). C-Kit mutations 
and the presence of estrogen-receptors were tested, 
but both markers were negative.
The patient was started on tamoxifen initially with 
20 mg/day, increasing up to 40 mg/day, but because 
of a diagnosis of cholelithiasis it was decreased again 
to 20 mg/day. However, due to disease progression 
with the appearance of new lesions (Figure 2A), 
the chemotherapy regimen with dacarbazine 
(300 mg/m2) and doxorubicin (20 mg/m2)—administered 
at day 1, 2, and 3, and repeated every 21 days—was 
approved by the Institutional Ethics Committee. 
This regimen was further switched, after eight 
cycles, to vinorelbine (25 mg/m2) and methotrexate 
(30 mg/m2) because of the patient’s intolerance 
(with myelosuppression) and the progression of 
the pelvic lesion—albeit with the regression of all 
others. There was a significant response to this last 
protocol—administered at day 1, 8, and 15, and 
repeated every 28 days—with dimensional regression 
of all lesions (Figure 2B) and pain resolution after 
14 cycles of chemotherapy.
DISCUSSION
DT may arise sporadically or in the context of 
an extra-colic manifestation of FAP, and may be 
intra-abdominal, located in the abdominal wall, or 
extra-abdominal.5,10,11 They comprise only 0.03% 
of all neoplasms and 3% of all soft tissue tumors. 
The majority of cases occur between the ages of 
15 and 60 years, with a peak incidence between 
25 and 35 years.16
Despite being considered benign tumors, due 
to the lack of metastasizing capability DT has great 
local aggressiveness and the potential for local 
recurrence.6,17 The most frequent locations are the 
small-bowel mesentery, followed by the abdominal 
wall, the extremities, and the trunk.12
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The etiology of this condition is still not well 
understood. However, trauma or muscle strain 
(like surgical stress) induces a disproportionate 
inflammatory response, with an accumulation of 
fibroblasts. Another theory is that there is an endocrine 
factor related to neoplasm, since DT are more common 
Figure 1. Photomicrograph of the retroperitoneal tumor. A – A sparse proliferation of elongated, slender, 
spindle-shaped cells of uniform appearance, set in a collagenous stroma (H&E); B – Cells with lack of hyperchromasia 
or atypia and with small, pale-staining nuclei. These cells are usually arranged in sweeping bundles (H&E); C – Lesion 
within the enteric wall (arrows) (H&E); D – Histochemistry showing strong expression of vimentin.
Figure 2. A – Abdominal magnetic resonance imaging (MRI) T1-weighted image, acquired in the axial plane, 
showing two new lesions (arrows); B – Abdominal MRI T1-weighted image, acquired in the axial plane, after 
chemotherapy, showing the regression of previous lesions.
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in women—either when they’re pregnant or using 
hormonal contraceptives, and some women develop 
the tumor without previous trauma.17,18
Therefore, surgical trauma may be implicated 
as one of the factors capable of leading to the 
development of DT, and appears unrelated to a specific 
type of surgery.8 Nevertheless, some authors observed 
a lower incidence of DT in laparoscopic versus open 
procedures, so minimally invasive approaches might 
presumably reduce the risk of the occurrence of DT 
after prophylactic colectomy in patients with FAP.10,19
The mutation site on the APC gene may also 
interfere with the risk of development of DT and its 
severity. Mutations located distally to codon 1309 and 
especially at the 3′ end, are associated with a high 
risk of developing DT, and particularly in a severe 
form.12,20,21 Bertario et al.8 stated that, in patients with 
FAP, mutations located beyond codon 1309 and codon 
1444 (“desmoid region”) increase 17-fold and 12-fold, 
respectively, the risk of DT development, compared 
with mutations located upstream.
In the case of intra-abdominal DT, the approach 
should be progressive,10 initially with observation,4 
followed by medical treatment, as the first line, 
with non-steroidal anti-inflammatory drugs (NSAIDs; 
e.g.  sulindac or celecoxib, with an efficacy rate close 
to 50%), or an anti-hormonal agent (tamoxifen or 
toremifene),14,22,23 even in estrogen receptor-free DT, 
because this therapy may still induce a response in that 
setting.24,25 If tumor progression persists, chemotherapy 
should be started.10,26 Surgery remains the final 
option10 in cases of resistance to medical treatment for 
symptomatic control, or resolution of tumor-related 
complications, such as intestinal obstruction, ischemia, 
enteric fistula, and hydronephrosis.1,27,28
However, in resectable extra-abdominal or 
abdominal wall DT, surgery may be an appropriate 
first-line treatment.29 Otherwise, a progressive 
approach similar to intra-abdominal DT is preferred.10
Although controversial, radiation therapy may 
be an alternative to surgery.30 Studies6,31 confirm the 
important role of such therapeutic modality in cases 
of unresectable abdominal wall,32 extra-abdominal DT, 
or after R1 resections. Either pre- or post-operatively, 
radiotherapy can model fibrosis, with the consequent 
decrease in local recurrence.14,33 In intra-abdominal 
DT, radiotherapy is rarely used, because of the low 
tumoral radiosensitivity10 and because of the risk of 
radiation enteritis.14
The role of chemotherapy in this setting was 
demonstrated by the efficacy of low doses of doxorubicin 
and dacarbazine, as well as the combination of 
methotrexate and vinblastine, in a progressive disease 
that did not respond to the medical therapy, which 
consisted in NSAIDs and anti-hormonal agents.26,34-36 
Other combination therapy that demonstrated good 
response was cyclophosphamide plus doxorubicin,26 
and doxorubicin plus tyrosine kinase inhibitors 
(TKI).37 For example, imatinib may have a role in the 
management of unresectable or difficult to resect DT.38 
Sorafenib, another TKI, demonstrated a response in DT, 
especially in the extra-abdominal variety, and may be 
an option when chemotherapy fails.37
CONCLUSION
These pat ients  should be managed by a 
multidisciplinary team, with individualized approaches 
and decisions. The strategy in intra-abdominal DT should 
be progressive, beginning with observation, followed 
by NSAIDs (e.g. sulindac), and/or an anti-hormonal 
agent (e.g. tamoxifen). If an unsatisfactory response 
persists and disease progression ensues, chemotherapy 
needs to be started. Surgery should be reserved for 
the final option, or for the resolution of tumor-related 
complications.
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